KR20200121817A - T 세포 계통의 세포를 생성하기 위한 방법 - Google Patents

T 세포 계통의 세포를 생성하기 위한 방법 Download PDF

Info

Publication number
KR20200121817A
KR20200121817A KR1020207024814A KR20207024814A KR20200121817A KR 20200121817 A KR20200121817 A KR 20200121817A KR 1020207024814 A KR1020207024814 A KR 1020207024814A KR 20207024814 A KR20207024814 A KR 20207024814A KR 20200121817 A KR20200121817 A KR 20200121817A
Authority
KR
South Korea
Prior art keywords
cells
cell
progenitor
notch ligand
lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207024814A
Other languages
English (en)
Korean (ko)
Inventor
후안 카를로스 주니가-플러커
마흐무드 모타샤미
애쉬튼 트로트만-그랜트
Original Assignee
서니브룩 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서니브룩 리서치 인스티튜트 filed Critical 서니브룩 리서치 인스티튜트
Publication of KR20200121817A publication Critical patent/KR20200121817A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020207024814A 2018-02-14 2019-02-14 T 세포 계통의 세포를 생성하기 위한 방법 Ceased KR20200121817A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630497P 2018-02-14 2018-02-14
US62/630,497 2018-02-14
PCT/CA2019/050181 WO2019157597A1 (en) 2018-02-14 2019-02-14 Method for generating cells of the t cell lineage

Publications (1)

Publication Number Publication Date
KR20200121817A true KR20200121817A (ko) 2020-10-26

Family

ID=67619677

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024814A Ceased KR20200121817A (ko) 2018-02-14 2019-02-14 T 세포 계통의 세포를 생성하기 위한 방법

Country Status (8)

Country Link
US (2) US12467034B2 (https=)
EP (1) EP3752602A4 (https=)
JP (3) JP2021514185A (https=)
KR (1) KR20200121817A (https=)
CN (1) CN112041431A (https=)
AU (2) AU2019220935B2 (https=)
CA (1) CA3091158A1 (https=)
WO (1) WO2019157597A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
JP2023548115A (ja) * 2020-10-28 2023-11-15 サンガモ セラピューティクス， インコーポレイテッド ヒト多能性幹細胞からのｃｄ４＋エフェクターおよび制御性ｔ細胞の生成
WO2022115492A1 (en) * 2020-11-24 2022-06-02 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
KR20230128324A (ko) * 2021-02-05 2023-09-04 고쿠리츠다이가쿠호진 고베다이가쿠 인공 다능성 줄기 세포 유래 γδ T 세포 및 그 제작방법
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
CN119365492A (zh) 2022-05-04 2025-01-24 世纪治疗股份有限公司 用hla-e和hla-g转基因工程化的细胞
JP2025522360A (ja) 2022-06-08 2025-07-15 センチュリー セラピューティクス，インコーポレイテッド Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
KR20250143301A (ko) 2022-11-10 2025-10-01 센츄리 쎄라퓨틱스 인코포레이티드 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도
WO2024156066A1 (en) * 2023-01-27 2024-08-02 Notch Therapeutics (Canada), Inc. Method for generating t cell lineage populations from stem/progenitor cells
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100895231B1 (ko) 2002-03-25 2009-05-04 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법
JP2006506322A (ja) 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
JP5756017B2 (ja) * 2008-11-07 2015-07-29 サニーブルック ヘルス サイエンシズ センター ヒト前駆ｔ細胞
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
ES2608937T3 (es) 2010-02-22 2017-04-17 Université Pierre Et Marie Curie (Paris 6) Medio de cultivo celular para el crecimiento y diferenciación de células del linaje hematopoyético
CN104053769A (zh) * 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
US10180254B2 (en) * 2014-09-16 2019-01-15 Hitachi Zosen Inova Ag Method and device for processing slag occurring in a combustion chamber of a refuse incineration plant
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
JP7049261B2 (ja) * 2016-04-08 2022-04-06 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント 幹細胞および／または前駆細胞からｔ前駆細胞を作製する方法ならびに該ｔ前駆細胞の使用
US20190134169A1 (en) 2016-04-26 2019-05-09 Temple University-Of The Commonwealth System Of Higher Education DLL4-expressing cells and vaccine using the same
IL268641B2 (en) 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
EP4326856A4 (en) * 2021-04-23 2025-10-08 Sunnybrook Res Inst STEM CELLS COMPRISING AN UNREARRANGED T CELL RECEPTOR (TCR) GENE LOCUS AND METHODS OF USE THEREOF
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof

Also Published As

Publication number Publication date
AU2019220935B2 (en) 2025-03-20
AU2025204516A1 (en) 2025-07-03
JP2021514185A (ja) 2021-06-10
US20200399599A1 (en) 2020-12-24
US12467034B2 (en) 2025-11-11
EP3752602A4 (en) 2021-11-24
JP2026031647A (ja) 2026-02-24
AU2019220935A1 (en) 2020-10-01
JP2024016217A (ja) 2024-02-06
WO2019157597A1 (en) 2019-08-22
US20260043003A1 (en) 2026-02-12
CN112041431A (zh) 2020-12-04
EP3752602A1 (en) 2020-12-23
CA3091158A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
US20260043003A1 (en) Method for generating cells of the t cell lineage
KR102651433B1 (ko) 혈관 콜로니 형성 세포
AU784928B2 (en) Hematopoietic differentiation of human embryonic stem cells
US20190330593A1 (en) Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
CN102144028B (zh) 造血前体的扩增
MXPA06006706A (es) Celulas madre.
WO2012133948A1 (ja) 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
WO2005097979A2 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
US12054743B2 (en) Method for obtaining T cells from pluripotent stem cells, and uses thereof
CN1898380B (zh) 从乳腺分泌物中分离细胞的方法
Wang et al. Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule
WO2000070022A9 (en) Ex vivo expansion of mammalian hematopoietic stem cells
US20030100107A1 (en) Compositions and methods for generating differentiated human cells
US20120177618A1 (en) Hematopoietic stromal progenitor cells and uses thereof
JP6861405B2 (ja) 造血系細胞の作製方法
US20250090578A1 (en) Method of producing a population of immune cells from pluripotent stem cells
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
KR100818215B1 (ko) Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
RU2797260C2 (ru) Способ получения предшественников т-клеток
Wang et al. ĐFerrata Storti Foundation
Kašėta et al. Magnetic cell sorting isolation of therapeutically effective BALB/c mouse bone marrow hematopoietic stem cell population
Class et al. Patent application title: HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF Inventors: Biju Parekkadan (Cambridge, MA, US) John Miles Milwid (Cambridge, MA, US) Martin Leon Yarmush (Newton, MA, US) Assignees: Massachusetts Institute of Technology THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL
JPWO1999003980A1 (ja) Ａｇｍ領域由来ストローマ細胞

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000